user avatar
Davide Capodanno
@DFCapodanno
Professor of Cardiology at University of Catania, Italy. Editor-in-Chief of @EuroInterventio.
Catania, Sicily
instagram.com/df_capodanno/
Joined March 2019
694
Following
22.6K
Followers
Posts
  • user avatar
    Davide Capodanno
    @DFCapodanno
    May 7, 2022
    Facts: 1) The CHA2DS2VASc score is not used to find patients who need anticoagulation, but those at low risk who do not. 2) The HAS-BLED score is not used to find patients at risk with anticoagulation, but to correct modifiable risk factors and "flag-up" for regular follow-up.
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Aug 29, 2020
    Five points I remember after a first reading of the @escardio NSTEACS guidelines, which may impact our practice: 1) Bye bye CK-MB 2) Do not pretreat with P2Y12i (including ticagrelor) 3) Prefer prasugrel in PCI 4) Very short TAT in AF 5) Angio in NSTEMI within 24 h #ESCCongress
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Sep 17, 2022
    With the evidence generated so far, we may safely conclude that PCI does not improve survival in patients with SIHD. PCI remains key in ACS, and for the improvement of PROMs in consideration of patient compliance and wishes in relation to the intensity of anti-anginals. #TCT2022
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Jul 20, 2023
    Three notable class 3 recommendations against routine periodic testing in asymptomatic CCD patients from AHA/ACC guidelines: 1) no benefit with coronary CTA or stress testing 2) no benefit of periodic assessment of LVEF 3) harm with coronary angiography jacc.org/doi/10.1016/j.…
    106K
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Feb 25, 2024
    Transcatheter mitral valve replacement (TMVR) devices that are currently undergoing clinical testing have a high anatomical screen failure rate due to challenges with annulus size or left ventricular outflow tract obstruction. The Saturn valve (InnovHeart) is a novel TMVR
    00:00
    92K
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Nov 16, 2019
    So, to recap: first I ask him about symptoms. If he is asymptomatic, I leave him alone. If he has symptoms, I ask a CCTA. If he has CAD on CCTA but not of the left main, then I explain the pros and cons of the invasive strategy. Finally I give him some colchicine. #AHA19
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Oct 22, 2020
    About aspirin for primary cardiovascular prevention. (I like this quote: "The best strategy for the use of aspirin in primary prevention may simply be to prescribe a statin instead." P. Ridker, NEJM 2018)
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Sep 20, 2022
    This state-of-the-art review reports a detailed overview of the history, indications and treatment strategies for recanalization of chronic total occlusions. eurointervention.pcronline.com/article/recana…
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Feb 17, 2024
    How a crazy idea led to a clinical revolution. "To all those who believe that we as cardiologists can make a difference in our commitment to ideas, TAVI stands as an example of what such an idea can produce." Rest in peace, Professor Cribier. eurointervention.pcronline.com/article/tavi-a…
    48K
  • user avatar
    Davide Capodanno
    @DFCapodanno
    May 23, 2020
    Cardiology: not necessarily the best and most interesting branch of medicine, but I study it because it is congenial to me and it is my job. Having said that, I think I have had enough of reading about poor studies of COVID19 drugs. When do we go back to talking about cardiology?
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Jan 19, 2024
    Where are we with drug-coated balloons (DCB) in PCI? Five thoughts. 1) The use of DCB in patients with in-stent restenosis, especially of a bare metal stent, is well established and evidence-based (now also in the US). 2) Conversely, DCB use in de novo disease lacks compelling
    33K
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Sep 18, 2022
    Trials comparing P2Y12 inhibitors. Prasugrel and ticagrelor are first-line therapies for patients with ACS; prasugrel should be preferred to ticagrelor in patients undergoing PCI. Clopidogrel is an alternative for patients at high risk of bleeding. SWITCH trial ongoing. #TCT2022
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Oct 2, 2020
    Spontaneous coronary dissections (SCAD): 1) are relatively uncommon, but represent one third of ACS causes in young women 2) are usually diagnosed by coronary angiography 3) heal spontaneously in the vast majority of patients 4) require CABG or PCI in selected cases
  • user avatar
    Davide Capodanno
    @DFCapodanno
    Mar 28, 2025
    Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor. 1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA 2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease 3. API-CAT
    40K